NUVL News and Press, Nuvalent Inc. From 03/31/22

Nuvalent Appoints Anna Protopapas as Chair of Board of Directors PR Newswire Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass. , March 31,...

Nuvalent press release (NASDAQ:NUVL): Q4 GAAP EPS of -$0.36 misses by $0.04. Cash, cash equivalents and marketable securities were $288.1 million as of December 31, 2021. For further details see: Nuvalent GAAP EPS of -$0.36 misses by $0.04

Nuvalent Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results PR Newswire NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors...

The following slide deck was published by Nuvalent, Inc. in conjunction with this event. For further details see: Nuvalent (NUVL) Investor Presentation - Slideshow

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 Data supports clinical investigation of NVL-520 and NVL-655 across various ROS1 or ALK fusion partners, resistance mutations, and tumor ty...

Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%.&#x...

Nuvalent to Participate in the Cowen 42nd Annual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , March 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for cli...

Nuvalent Appoints Emily Drabant Conley, PhD, to Board of Directors Industry-leading genomics expertise supports Nuvalent's advancement as a clinical-stage precision oncology company PR Newswire CAMBRIDGE, Mass. , Feb. 3, 2022 /PRNewswire/ -- Nuvalent, In...

Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor ARROS-1 trial enrolling patients with advanced ROS1-positive NSCLC and other solid tumors Clinical development for parallel lead program, NVL-655, in ALK...

Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Jan. 4, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically...